Phyla Launches High-Potency Phage Serum for Professional Acne Treatments

The new professional-use formula brings Phyla's targeted phage technology into pore-opening treatments with 8x the phage concentration of their consumer serum.



NEW YORK, NY, UNITED STATES, September 16, 2026 /EINPresswire.com/ -- Phyla, the microbiome-focused acne skincare company pioneering bacteriophage technology for acne-prone skin, announced today the launch of Phyla PRO Precision Phage Serum, a professional-use, high-potency phage serum developed specifically for in-office acne-prone skin protocols.

Designed for application during or immediately after pore-opening aesthetic procedures, Phyla PRO delivers targeted bacteriophages to help reduce acne-associated Cutibacterium acnes (C. acnes) while preserving the broader skin microbiome. With 8x the phage concentration of Phyla's consumer Acne Phage Serum, Phyla PRO extends the company's phage technology from daily at-home skincare into the professional treatment room.

Phyla's findings build on a growing body of peer-reviewed research evaluating C. acnes-targeting bacteriophages. Research published in Nature Communications in 2023 reported reductions in bacterial load and inflammation in an in-vivo acne model, while a 2026 proof-of-concept study in Scientific Reports found that topical C. acnes phage therapy reduced inflammatory and non-inflammatory acne lesions in humans while selectively sparing other skin bacteria.

Phyla PRO has undergone Human Repeat Insult Patch Testing, with no irritation or sensitization observed under HRIPT conditions. The formula is made without fragrance, parabens, phthalates, alcohol, benzoyl peroxide or drying agents. Phyla PRO requires refrigerated storage at 2–8°C / 36–46°F when not in use to maintain phage efficacy.

About Phyla
Phyla is a biotechnology-driven skincare company pioneering the use of bacteriophages to selectively target bacteria associated with skin conditions while preserving the broader skin microbiome. Its patented phage technology is designed to offer a precise, microbiome-conscious approach to acne-prone skin.

Executive Contact
Neil Giugno
CEO, Phyla
neil@phyla.com

Scientific References
Van Prooyen N, et al. Randomized Controlled Study of Bacteriophages in Acne Reveals Efficacy and Novel Mechanism for Promoting Long-Term Skin Health. Journal of Drugs in Dermatology. 2026;25(6):523.
Rimon A, et al. Nature Communications. 2023;14:1005.
Trejo-Hernández A, et al. Scientific Reports. 2026;16:10184.

Neil Giugno
Phyla
+1 6462495280
email us here
Visit us on social media:
Instagram

This press release can be viewed online at: https://www.einpresswire.com/article/942867238

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.